阿立哌唑与利培酮的疗效和安全性比较

Comparison of efficacy and safety of Aripiprazole and Risperidone in the treatment of schizophrenia

目的:比较阿立哌唑与利培酮治疗精神分裂症的疗效和安全性。方法:将60例符合CCMD-3诊断标准的精神分裂症病人随机分为两组,分别给予阿立哌唑和利培酮治疗8周。于治疗前和治疗后1、2、4、8周末采用阳性症状和阴性症状量表(PANSS)评定临床疗效,副反应量表(TESS)评定不良反应。结果:治疗8周后,两组疗效无显著性差异(P>0.05),阿立哌唑组的不良反应发生率低干利培酮组,但差异无显著性(P>0.05)。利培酮组锥体外系不良反应和内分泌改变的发生均明显高于阿立哌唑组(P<0.05)。结论:阿立哌唑和利培酮对精神分裂症疗效相当,不良反应轻,但表现有异同。两种物药均为疗效好、安全性高的抗精神病药,有利于提高病人用药的依从性。

Objective： To compare efficacy and safety of Aripiprazole and Risperidone in the treatment of schizophrenia. Methods：60 patients with schizophrenia by CCMD -3 were randomly allocated to two groups treated with Aripiprazole or Risperidone for 8 weeks. The Positive. and Negative Syndrome Scale（PANSS） and Treatment Emergent Symptoms Scale （TESS） were used to evaluate efficacy and adverse effects respectively before treatment and at the end of 1,2,4 and 8 weeks. Results： The therapeutic efficacy in Aripiprazole group was similar to that in Risperidone （ P 〉 0.05 ） ; There was no significant difference between the two groups （ P 〉 0. 05 ）. Incidence of adverse effects in the Aripiprazole group was lower than that in the Risperidone group, but the difference was not significant（ P 〉0.05 ）. The rates of extra- pyramidal symptoms and endocrine change were significantly higher in the Risperidone group than those in the Aripiprazole group. Conclusions： The results suggest that Aripiprazole is as effective as Risperidone for the treatment of schizophrenia and fewer side effects in them, although two drugs have different or the same side effects profile., They both are efficacy and safety antipsychotic drugs in treatment of schizophrenia . They are beneficial to improve the therapeutic compliance of schizophrenic patients.